Walleye Capital’s Akero Therapeutics AKRO Stock Holding History

Walleye Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,323	Closed	-$161K	–	4423
2025 Q2	$177K	Sell	3,323 -69,661	-95%	-$3.17M	﹤0.01%	3454
2025 Q1	$2.95M	Sell	72,984 -61,721	-46%	-$2.62M	0.01%	1151
2024 Q4	$3.75M	Buy	+134,705	New	+$4.08M	0.01%	1276
2024 Q3	–	Sell	-23,707	Closed	-$556K	–	5204
2024 Q2	$556K	Buy	23,707 +12,627	+114%	+$270K	﹤0.01%	3419
2024 Q1	$280K	Sell	11,080 -118,937	-91%	-$2.86M	﹤0.01%	3709
2023 Q4	$3.04M	Buy	+130,017	New	+$2.56M	0.01%	1470
2023 Q3	–	Sell	-59,677	Closed	-$2.79M	–	4819
2023 Q2	$2.79M	Sell	59,677 -45,755	-43%	-$2.1M	0.01%	1097
2023 Q1	$4.03M	Buy	105,432 +15,864	+18%	+$707K	0.06%	400
2022 Q4	$4.91M	Sell	89,568 -114,475	-56%	-$4.9M	0.09%	269
2022 Q3	$6.95M	Buy	+204,043	New	+$3.12M	0.13%	165

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Walleye Capital's AKRO Position: Q3 2025 in Review

Walleye Capital sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 3,323 shares — an estimated $161K sold.

Walleye Capital first reported a position in AKRO in Q3 2022 and held it in 10 quarters. The position peaked at $6.95M in Q3 2022. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

Walleye Capital reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
Walleye Capital sold 3,323 Akero Therapeutics shares in Q3 2025, an estimated $161K.
Walleye Capital first reported a position in Akero Therapeutics in Q3 2022 and held it in 10 quarters.
Walleye Capital's Akero Therapeutics position peaked at $6.95M in Q3 2022.
265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.